



In the United States Patent and Trademark Office

#529
RECEIVED 6/03
AUG 14 2003
C. Stale

TECH CENTER 1600/2900

In re application: Stable Pharmaceutical
Compositions

Art Unit: 1624

Application No.: 10/087,951

Examiner Name: Emily B Bernhardt

Filed: 03/05/2002

Inventor Name(s): Donald L. Barbeau

Docket No.: Barbeau 0302

Commissioner of Patents and Trademarks
Washington, DC 20231

Response to Restriction Requirement

Dear Sir:

This letter is in response to an Office Action dated July 8, 2003 from Examiner Bernhardt relating to the above-identified patent application in which Examiner Bernhardt entered a restriction requirement under 35 U.S.C. §121. The examiner indicated that the Applicant's Claims 1-20 and 30-38 to a method of employing phthalazine hydrazones and compositions thereof are drawn to a distinct invention from the phthalazine hydrazones in Claims 21-29.

In reply to the examiner's restriction requirement, Applicant hereby elects, without traverse, Claims 1-20 and 30-38 for prosecution in this application.


Please send all further correspondence with this application be sent to the sole inventor at the following address: **Donald L. Barbeau at Barbeau Pharma, Inc. 6 Williamsburg Circle, Evanston, Illinois 60203 (847)254-8532.**

Respectfully submitted


Donald L. Barbeau, Inventor
Registration No. 29,766

Certificate of Mailing

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner of Patents and Trademarks, Washington DC 20231 on the date shown below:


Donald L. Barbeau
August 4, 2003